Document ID: S_2_05
Section: S_Future_Technology
Keywords: longevity, aging, geroscience, Hayflick limit, telomere, telomerase, Elizabeth Blackburn, caloric restriction, rapamycin, mTOR, hallmarks of aging, senolytics, dasatinib, quercetin, NAD+, NMN, NR, nicotinamide, metformin, TAME trial, Yamanaka factors, partial reprogramming, parabiosis, GDF11, SENS, Aubrey de Grey, cryonics, Alcor, life extension, sirtuin, resveratrol, epigenetic clock, Horvath clock
Category Tags: future-technology, genetics, artificial-intelligence
Cross-References: ZB_2_05 · B_2_04 · A_1_08 · S_2_04 · L_2_01
Reliability Tier: Tier 1-3 (ranges from Nobel Prize-winning telomere biology to speculative cryonics and radical life extension)
Last Updated: Feb 28, 2026 | Source Count: 22 | Weighted Score: 42 | Source Confidence: [5/5] | Confidence: High (Tier 1), Moderate (Tier 2), Low-Moderate (Tier 3-4)

QUICK SUMMARY

Aging — the progressive decline in physiological function leading to increased vulnerability, disease, and death — has transitioned from an accepted inevitability to a legitimate target of biomedical intervention. The field of geroscience investigates the biological mechanisms of aging with the goal of extending healthy lifespan ("healthspan") rather than merely total years alive. Key milestones include the discovery of the Hayflick limit (1961), the identification of telomeres and telomerase (Blackburn, Greider, and Szostak; Nobel Prize 2009), the demonstration that caloric restriction extends lifespan across species, the identification of the mTOR pathway as a central aging regulator (rapamycin extends mouse lifespan, 2009), and the formulation of the "Hallmarks of Aging" framework (López-Otín et al., 2013). Current therapeutic frontiers include senolytics (drugs that eliminate senescent cells), NAD+ precursor supplementation, metformin trials for aging (TAME), Yamanaka factor-based cellular reprogramming, and parabiosis research. The field exists in tension between rigorous academic geroscience and a commercial "longevity industry" of variable scientific quality, alongside radical visions of biological immortality (SENS/de Grey) and post-mortem preservation (cryonics). Ancient myths of extreme longevity and immortality (Sumerian King List, Biblical patriarchs, Daoist immortals) provide cultural context for humanity's enduring aspiration to transcend mortality.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Nobel Prize-Level Science)

1.1 The Hayflick Limit and Cellular Senescence

• Discovery (1961): Leonard Hayflick and Paul Moorhead demonstrated that normal human cells divide a finite number of times in culture (~50–70 divisions for fetal fibroblasts) before entering a state of irreversible growth arrest — "replicative senescence." This overturned Alexis Carrel's earlier (erroneous) claim that cells were inherently immortal. The Hayflick limit established that aging has a cellular basis.
• Senescence phenotype: Senescent cells remain metabolically active but cease dividing and develop a distinctive Senescence-Associated Secretory Phenotype (SASP) — secreting inflammatory cytokines (IL-6, IL-8), growth factors, proteases, and chemokines. SASP drives chronic inflammation ("inflammaging"), tissue dysfunction, and promotes age-related diseases including cancer, atherosclerosis, osteoarthritis, and neurodegeneration.
• Accumulation: Senescent cells accumulate with age, comprising up to 15–20% of cells in aged tissues. Their removal (via genetic or pharmacological means) extends healthspan and lifespan in mouse models (Baker et al., Nature, 2011, 2016).

1.2 Telomere Biology (Nobel Prize 2009)

Elizabeth Blackburn, Carol Greider, and Jack Szostak received the Nobel Prize in Physiology or Medicine for discovering how chromosomes are protected by telomeres and the enzyme telomerase:

• Telomeres: Repetitive DNA sequences (TTAGGG in humans, ~5,000–15,000 bases at birth) capping chromosome ends. They prevent end-to-end fusion and protect coding DNA during replication. Each cell division shortens telomeres by ~50–200 bases (the "end-replication problem").
• Telomerase: A reverse transcriptase enzyme that adds telomeric repeats, counteracting shortening. Telomerase is active in stem cells, germ cells, and ~90% of cancers. It is largely repressed in most somatic cells — creating the replicative countdown that enforces the Hayflick limit.
• Epigenetic clocks (Horvath, 2013): Steve Horvath developed a DNA methylation-based "epigenetic clock" that predicts biological age from methylation patterns at ~353 CpG sites across the genome. Biological age (as measured by the Horvath clock) can diverge significantly from chronological age and correlates with all-cause mortality and disease risk. Second-generation clocks (GrimAge, PhenoAge) incorporate clinical biomarkers for improved mortality prediction.
• Telomere-aging relationship: Short telomeres correlate with aging and age-related disease, but the relationship is not straightforwardly causal — telomere length is influenced by genetics, stress, inflammation, and lifestyle. Forced telomerase expression in mice extends lifespan but also increases cancer risk, illustrating the tension between replicative capacity and tumor suppression.

1.3 Caloric Restriction — The Most Robust Lifespan Intervention

• Discovery: Clive McCay (Cornell, 1935) demonstrated that caloric restriction (CR) — reducing caloric intake 20–40% below ad libitum without malnutrition — extends lifespan in laboratory rats by ~30–50%.
• Cross-species consistency: CR extends lifespan in yeast, worms (C. elegans), flies (Drosophila), fish, mice, and rats. This extraordinary conservation across phylogenetically distant species suggests CR engages fundamental, ancient nutrient-sensing pathways.
• Primate data: Two long-term studies in rhesus macaques produced initially conflicting results — Wisconsin National Primate Research Center (Colman et al., Science, 2009; Nature Communications, 2014) showed ~30% reduction in age-related mortality with CR, while NIA (Mattison et al., Nature, 2012) showed no significant lifespan extension. Differences in diet composition, onset age, and control group feeding explained the discrepancy. A 2017 collaborative reanalysis (Mattison et al., Nature Communications) confirmed healthspan benefits in both studies.
• Mechanisms: CR activates longevity-associated pathways including AMPK (AMP-activated protein kinase), sirtuins (SIRT1-7), and inhibits mTOR and insulin/IGF-1 signaling — all of which shift cellular metabolism toward repair, autophagy, and stress resistance rather than growth and reproduction.

1.4 The mTOR Pathway and Rapamycin

• mTOR (mechanistic Target of Rapamycin): A serine/threonine kinase central to cell growth, proliferation, and metabolism. Functions as a nutrient and growth factor sensor — when nutrients are abundant, mTOR promotes growth; when scarce, mTOR inhibition promotes autophagy and cellular maintenance.
• Rapamycin: A macrolide compound discovered in soil bacteria on Easter Island (Rapa Nui, hence the name). Originally developed as an immunosuppressant and anticancer agent. Harrison et al. (Nature, 2009) demonstrated that rapamycin extended median mouse lifespan by 9–14% even when treatment began at 20 months of age (equivalent to ~60 human years) — the first pharmacological extension of lifespan in genetically normal mammals. The finding was independently replicated by the NIA Interventions Testing Program (ITP) across three sites.
• Clinical translation: Rapamycin's immunosuppressive effects complicate direct human application. Low-dose intermittent rapamycin protocols are under investigation (e.g., Mannick et al., Science Translational Medicine, 2014, showed improved immune function in elderly subjects with a rapamycin analog, everolimus). Several clinical trials for aging-related applications are underway.
• Rapalogs: Rapamycin analogs (everolimus, temsirolimus) are FDA-approved for transplant rejection and specific cancers. Their anti-aging potential is being explored off-label and in formal trials.

1.5 The Hallmarks of Aging Framework

López-Otín et al. (Cell, 2013, updated 2023) proposed a taxonomy of nine (later twelve) hallmarks — biological processes that contribute to aging and whose experimental manipulation can accelerate or decelerate aging:

• Original nine (2013): Genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
• Added (2023): Disabled macroautophagy, chronic inflammation, and dysbiosis (microbiome imbalance).
• Utility: The framework provides a systematic map for intervention — each hallmark represents a potential therapeutic target. Senolytics address cellular senescence; rapamycin addresses deregulated nutrient sensing; NAD+ precursors address mitochondrial dysfunction; Yamanaka factors address epigenetic alterations.

2. CREDIBLE CLAIMS (Tier 2 — Active Research / Clinical Trials)

2.1 Senolytics — Clearing Senescent Cells

• Concept: Pharmacological agents that selectively kill senescent cells while sparing healthy cells, eliminating the inflammatory SASP and restoring tissue function.
• D+Q (Dasatinib + Quercetin): The first senolytic combination identified (Zhu et al., Aging Cell, 2015). Dasatinib (a tyrosine kinase inhibitor) targets senescent fat cell progenitors; quercetin (a plant flavonoid) targets senescent endothelial cells. Intermittent D+Q treatment extended healthspan and lifespan in mice. First human trial (Mayo Clinic, 2019) showed reduced senescent cell markers in idiopathic pulmonary fibrosis patients — proof of concept for human senolytic therapy.
• Fisetin: A natural flavonoid (found in strawberries) with senolytic properties. The AFFIRM trial (Mayo Clinic) is testing fisetin in elderly adults. Results pending as of 2025.
• Unity Biotechnology: Founded 2011; lead candidate UBX0101 (senolytic for osteoarthritis) failed Phase 2 in 2020. The company pivoted to ophthalmology (diabetic macular edema). The failure highlighted challenges in translating mouse senolytic results to human disease.
• Challenges: Identifying biomarkers for in vivo senescent cell burden, dosing schedules (intermittent vs. chronic), tissue specificity of senolytic agents, and potential risks of clearing senescent cells needed for wound healing or tumor suppression.

2.2 NAD+ Precursors — NMN, NR, and the Sirtuin Connection

• NAD+ decline: Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential for energy metabolism, DNA repair, and sirtuin activity. NAD+ levels decline ~50% between ages 40 and 60 (Camacho-Pereira et al., Cell Metabolism, 2016). This decline is implicated in metabolic dysfunction, neurodegeneration, and inflammation.
• Precursors: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursor supplements that elevate NAD+ levels in humans. NR received GRAS status (FDA, 2016). Clinical trials demonstrate elevated NAD+ levels; improvements in functional outcomes (endurance, cognition, metabolic markers) have been inconsistent across studies.
• Sirtuin controversy: Sirtuins (SIRT1-7) are NAD+-dependent deacetylases linked to CR-mediated lifespan extension. The sirtuin-resveratrol hypothesis (popularized by David Sinclair, Harvard) proposed that resveratrol activates SIRT1 and mimics CR benefits. GSK purchased Sirtris Pharmaceuticals for $720M (2008) based on this premise; the program was subsequently discontinued. The sirtuin field remains active but more cautious in its therapeutic claims.

2.3 Metformin and the TAME Trial

• Metformin: The most prescribed type 2 diabetes medication worldwide (~150 million prescriptions/year). Observational studies (Bannister et al., Diabetes, Obesity and Metabolism, 2014) showed that diabetic patients on metformin had 15% lower all-cause mortality than matched non-diabetic controls — suggesting anti-aging effects beyond glucose control.
• TAME (Targeting Aging with Metformin): Led by Nir Barzilai (Albert Einstein College of Medicine), this landmark trial aims to test whether metformin delays the composite outcome of age-related diseases (cardiovascular disease, cancer, dementia, death) in 3,000 non-diabetic adults aged 65–79. TAME is significant not only for testing metformin but for establishing aging itself as an FDA-approvable indication — potentially opening the regulatory pathway for all anti-aging therapeutics. Trial enrollment ongoing as of 2025.
• Mechanism: Metformin activates AMPK, inhibits mitochondrial complex I, and reduces mTOR signaling — overlapping with CR pathways. It also modulates the gut microbiome (Wu et al., Nature Medicine, 2017).

2.4 Yamanaka Factors and Cellular Reprogramming

• Discovery (Nobel Prize 2012): Shinya Yamanaka demonstrated that four transcription factors (Oct4, Sox2, Klf4, c-Myc — "OSKM" or "Yamanaka factors") can reprogram adult somatic cells into induced pluripotent stem cells (iPSCs) — resetting their epigenetic age to an embryonic state.
• Partial reprogramming: Ocampo et al. (Cell, 2016) showed that cyclical, short-term expression of OSKM in progeria mice reversed age-related epigenetic signatures, improved tissue function, and extended lifespan by 30% — without causing teratomas (cancers associated with full reprogramming). This demonstrated that epigenetic aging can be uncoupled from cell identity — rejuvenation without dedifferentiation.
• Altos Labs (2022): Founded with $3 billion in funding (Jeff Bezos among investors) to pursue cellular reprogramming for rejuvenation. Recruited top aging researchers including Juan Carlos Izpisúa Belmonte, Steve Horvath, and Shinya Yamanaka as senior advisor. Represents the largest single private investment in longevity research.
• Retro Biosciences and other startups: Multiple companies pursuing in vivo or ex vivo partial reprogramming approaches. Key challenges include controlling reprogramming depth (too little = no effect; too much = cancer), delivery methods, and tissue specificity.

3. SPECULATIVE CLAIMS (Tier 3 — Early-Stage / Debated)

3.1 Parabiosis — Young Blood Research

• Heterochronic parabiosis: Surgical joining of circulatory systems between young and old mice. Conboy et al. (Nature, 2005) demonstrated that old mice surgically connected to young mice showed improved muscle regeneration, liver function, and neural stem cell activity. Young mice connected to old mice showed accelerated aging phenotypes — suggesting circulating factors that promote or inhibit aging.
• GDF11 controversy: Wagers et al. (Science, 2014) identified GDF11 (Growth Differentiation Factor 11) as a circulating rejuvenation factor declining with age. However, Egerman et al. (Cell Metabolism, 2015) challenged these findings, arguing that assay cross-reactivity confounded the results and that GDF11 levels may not actually decline with age. The debate remains unresolved.
• Human trials: Ambrosia LLC (Jesse Karmazin) marketed young blood transfusions ($8,000/liter) commercially — the FDA issued a warning statement (2019) that "plasma from young donors is not proven to provide clinical benefit" and cautioned against the practice. The company ceased operations.
• Dilution hypothesis: The Conboy lab (2020) demonstrated that diluting old blood plasma with saline and albumin — without adding young blood — reproduced many of parabiosis's rejuvenating effects, suggesting that removing pro-aging factors in old blood is more important than adding young factors.

3.2 SENS and Radical Life Extension

• SENS (Strategies for Engineered Negligible Senescence): Framework proposed by Aubrey de Grey (2005–) identifying seven categories of cellular and molecular damage that accumulate with aging, with proposed repair strategies for each. The SENS Research Foundation has funded research on mitochondrial gene therapy, senescent cell clearance, advanced glycation end-product (AGE) breaking, and amyloid clearance.
• De Grey's predictions: De Grey famously claimed that the first person to live to 1,000 may already be alive — based on the concept of "longevity escape velocity" (where life-extending therapies are developed faster than people age). This claim is not supported by current evidence but functions as a motivational framing for the field.
• Institutional controversy: De Grey was removed from the SENS Research Foundation in 2021 following sexual harassment allegations, complicating the public face of the radical life extension movement.
• Academic reception: Mainstream geroscientists generally regard SENS as an interesting conceptual framework but view the timeline claims as wildly optimistic. The seven damage categories have scientific basis; the feasibility of comprehensive repair within decades is contested.

3.3 Cryonics — Preservation for Future Revival

• Concept: Preserving deceased individuals (or just their heads — "neuropreservation") at liquid nitrogen temperatures (-196°C) with the expectation that future technology will enable revival and cure of the cause of death.
• Organizations: Alcor Life Extension Foundation (Scottsdale, Arizona; ~1,400 members, ~230 patients preserved as of 2024) and Cryonics Institute (Clinton Township, Michigan; ~2,000 members, ~250 patients). Cost: $200,000 (full body, Alcor) or ~$28,000 (CI).
• Scientific basis: Vitrification (replacing water with cryoprotectant solutions to prevent ice crystal formation) can preserve cellular ultrastructure. Aldehyde-stabilized cryopreservation (ASC) demonstrated near-perfect neural connectome preservation in rabbit and pig brains (McIntyre & Bhonsle, 2015) — winning the Brain Preservation Foundation Prize.
• Critical unknowns: Whether preserved information (memories, personality, identity) survives the cryopreservation process; whether future technology could repair cryoinjury and reverse death; whether the identity of a revived person would be continuous with the original. These are not merely technical challenges but philosophical questions about the nature of personal identity.
• Legal status: Cryopreservation is performed only after legal death. No cryonics organization claims current ability to revive patients. The practice is legal in the U.S. and a few other jurisdictions.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Evidence)

4.1 "Resveratrol Supplements Extend Human Lifespan"

Despite significant media hype, large-scale human studies have not demonstrated lifespan extension from resveratrol supplementation. The JAMA Internal Medicine (Semba et al., 2014) study of an Italian cohort found no association between urinary resveratrol metabolites and longevity, cardiovascular disease, or cancer. Therapeutic concentrations achieved in cell culture and mouse studies are far higher than attainable through oral supplementation. The wine-based "French Paradox" explanation is better attributed to statistical confounders and moderate alcohol consumption effects.

4.2 "Ancient Patriarchs Lived 900+ Years Literally"

Biblical patriarchs (Methuselah: 969 years, Noah: 950 years, Adam: 930 years — Genesis 5) and Sumerian King List entries (kings reigning 28,800–43,200 years) are presented literally by some traditions. Assessment: These figures likely represent numerological symbolism, different calendrical systems, or mythological conventions common to ancient Near Eastern literature. No biological mechanism is known that could support such extreme longevity; the maximum documented human lifespan is 122 years (Jeanne Calment, 1875–1997). (→ B_2_04)

4.3 "Immortality Is Achievable Within 20 Years"

Claims of imminent biological immortality (sometimes attributed to Ray Kurzweil's prediction of "longevity escape velocity" by ~2030) dramatically understate the complexity of aging biology. While significant healthspan extension may be achievable, the non-linear escalation of frailty, dementia, cancer, and organ failure beyond ~100 years suggests inherent biological constraints. No current therapy has extended maximum human lifespan beyond ~120 years.

4.4 "Growth Hormone Is an Anti-Aging Miracle"

Human growth hormone (HGH) is marketed in anti-aging clinics for body composition improvement, energy, and "rejuvenation." While HGH increases lean mass and decreases fat mass in elderly subjects, clinical trials show no improvement in functional outcomes (strength, endurance, cognition) and increased adverse effects (joint pain, carpal tunnel, diabetes risk). The 1990 Rudman et al. (NEJM) study — frequently cited by anti-aging clinics — involved only 12 men, lasted 6 months, and the journal's editors subsequently stated the results were misrepresented by the anti-aging industry. HGH supplementation may actually shorten lifespan: reduced growth hormone/IGF-1 signaling extends lifespan in mice, worms, and flies.

4.5 "Telomere Supplement Products Reverse Aging"

Consumer products marketed as "telomere lengthening" supplements (TA-65, derived from Astragalus extract) lack robust evidence of meaningful telomere elongation or lifespan extension in humans. The relationship between telomere length and aging is correlative, not simply causal, and forced telomere extension could increase cancer risk.

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims presented here. The topic of Longevity Research represents established knowledge within future technology and innovation with no active scholarly dispute over the fundamental claims presented in this document.

IMAGES

BIBLIOGRAPHY

1. Hayflick, L.; Moorhead, P.S. . , 25, 585 621 | 1961 | "The serial cultivation of human diploid cell strains" | Experimental Cell Research | ∅ | ∅ | ∅ | ∅ | doi:10.1016/0014-4827(61)90192-6 | ∅ | ∅ | ∅
2. Blackburn, E.H., Greider, C.W.; Szostak, J.W. | 2009 | "Telomeres and Telomerase" | ∅ | ∅ | ∅ | Nobel Prize Lectures: Nobel Foundation | ∅ | doi:10.4161/cbt.8.20.10237 | ∅ | ∅ | ∅
3. López-Otín, C., et al. . , 153(6), 1194 1217 | 2013 | "The hallmarks of aging" | Cell | ∅ | ∅ | ∅ | ∅ | doi:10.1016/j.cell.2013.05.039 | ∅ | ∅ | ∅
4. López-Otín, C., et al. . , 186(2), 243 278 | 2023 | "Hallmarks of aging: An expanding universe" | Cell | ∅ | ∅ | ∅ | ∅ | doi:10.1016/j.cell.2022.11.001 | ∅ | ∅ | ∅
5. Harrison, D.E., et al. . , 460, 392 395 | 2009 | "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice" | Nature | ∅ | ∅ | ∅ | ∅ | doi:10.1038/nature08221 | ∅ | ∅ | ∅
6. Baker, D.J., et al. . , 530, 184 189 | 2016 | "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan" | Nature | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Zhu, Y., et al. . , 14(4), 644 658 | 2015 | "The Achilles' heel of senescent cells" | Aging Cell | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Horvath, S. . , 14, R115 | 2013 | "DNA methylation age of human tissues and cell types" | Genome Biology | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Ocampo, A., et al. . , 167(7), 1719 1733 | 2016 | "In vivo amelioration of age-associated hallmarks by partial reprogramming" | Cell | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Conboy, I.M., et al. . , 433, 760 764 | 2005 | "Rejuvenation of aged progenitor cells by exposure to a young systemic environment" | Nature | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Colman, R.J., et al. . , 325(5937), 201 204 | 2009 | "Caloric restriction delays disease onset and mortality in rhesus monkeys" | Science | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. Mannick, J.B., et al. . , 6(268), 268ra179 | 2014 | "mTOR inhibition improves immune function in the elderly" | Science Translational Medicine | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Yamanaka, S. | 2012 | "The Winding Road to Pluripotency" | ∅ | ∅ | ∅ | Nobel Prize Lecture: Nobel Foundation | ∅ | ∅ | ∅ | ∅ | ∅
14. de Grey, A.D.N.J. . | 2007 | ∅ | Ending Aging | ∅ | ∅ | St | ∅ | isbn:9780312367060 | ∅ | ∅ | Martin's Press
15. Camacho-Pereira, J., et al. . , 23(6), 1127 1139 | 2016 | "CD38 dictates age-related NAD decline" | Cell Metabolism | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
16. Bannister, C.A., et al. . , 16(11), 1165 1173 | 2014 | "Can people with type 2 diabetes live longer than those without?" | Diabetes, Obesity and Metabolism | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
17. Mattison, J.A., et al. . , 8, 14063 | 2017 | "Caloric restriction improves health and survival of rhesus monkeys" | Nature Communications | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
18. Kenyon, C. . , 464, 504 512 | 2010 | "The genetics of ageing" | Nature | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
19. Fontana, L., Partridge, L.; Longo, V.D. . , 328(5976), 321 326 | 2010 | "Extending healthy life span — from yeast to humans" | Science | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
20. Kirkwood, T.B.L. . , 120(4), 437 447 | 2005 | "Understanding the odd science of aging" | Cell | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
21. Semba, R.D., et al. . , 174(7), 1077 1084 | 2014 | "Resveratrol levels and all-cause mortality in older community-dwelling adults" | JAMA Internal Medicine | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
22. McIntyre, R.L.; Bhonsle, S. | 2015 | "Aldehyde-Stabilized Cryopreservation" | ∅ | ∅ | ∅ | Brain Preservation Foundation Prize | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Consolidated from 22 sources. Last Updated: Feb 28, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/0014-4827(61)90192-6. Corpus hygiene campaign, Phase 4, 2026-07-29.